Anavex Life Sciences Corp (AVXL)

[falconer66a]

Paper Supports Sigma-2 Receptor Agonists for Parkinson's Disease

Thanks for posting the link. To read the entire article one needs to fork over $35. Saved my dollars, just read the posted abstract; good enough.

In essence, the paper illustrates how restoration of sigma-1 receptor function (exactly what the Anavex sigma-1 receptor agonists do) can restore dopamine levels produced by dopaminergic neurons of the substantia nigra (SN) region of the brain. Disruption of normal dopaminergic functions is the root cause of most Parkinson's disease symptoms. Fix the dopamine deficiency problem in the substantia nigra, and Parkinson's is fixed.

Now Anavex was not mentioned at all in the article. It was not focused on any of the Anavex molecules; instead, it focused on just why neurons in the substantia nigra fail to produce adequate dopamine, causing Parkinson's symptoms. And the reason for that is because dysfunctioning sigma-1 receptors cause death of dopamine-producing neurons. Again, the Anavex molecules restore normal sigma-1 receptor function (they are "agonists," good-condition-promotors).

This paper portends very favorable results in the up-coming 12-week Anavex 2-73 Parkinson's clinical trial.

Just another of many technical papers telling the detailed profound molecular and cytological science of the Anavex molecules.

The Anavex science is solid, as supported, again, by this paper.

About 5 million people in just Western Europe have Parkinson's Disease.